Letter 1 - NIH Triage

The Scientist, Sept. 5, 1994, page 13), contains several misperceptions. While it is true that the use of triage in peer review would relieve some pressure on review staff at the National Institutes of Health, it has never been suggested, as Musacchio implies, that it would "solve the problems undermining American science." As now applied at NIH, triage focuses on reducing time spent at review meetings by eliminating discussion on a

Written byHugh Stamper
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

As now applied at NIH, triage focuses on reducing time spent at review meetings by eliminating discussion on applications whose scores would fall below the committee's midpoint (50th percentile) and are unlikely to be changed by further discussion. These noncompetitive applications, however, are carefully reviewed in advance of the meeting. In fact, reviewers report spending the same amount of time evaluating applications that are ultimately deemed noncompetitive under triage as they did when triage was not used. Reviewers prepare written comments in advance of the meeting, as they have always done.

Contrary to Musacchio's perception, under triage, all applicants receive summary statements. Furthermore, the use of triage has facilitated the move from summary statements composed of carefully integrated comments to those in which reviewers' prepared comments are released intact and virtually unedited. Thus, contrary to the suggestion that reviewers are no longer accountable to applicants receiving a noncompetitive rating, reviewers ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies